Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

AGNC Investment (AGNC) Beats Stock Market Upswing: What Investors Need to Know

AGNC Investment closed at $10.94, up 1.2% and outpacing the S&P 500's 0.72% gain. The REIT is expected to report EPS of $0.39 (up 11.43% YoY) and revenue of $428.4 million (up 189.46% YoY). However, the stock has lagged over the past month and carries a Zacks Rank #3 (Hold) rating with a Forward P/E of 6.78, trading at a discount to its industry average.

If You'd Invested $10,000 in Each of These 3 High-Yield Stocks 10 Years Ago, Here's How Much Income You'd Collect Today

A comparison of three high-yield dividend stocks over the past decade reveals that dividend growth matters more than initial yield. AGNC Investment's dividend income fell 33% due to interest rate changes, while Ares Capital grew dividends 26% and ONEOK increased them 74%. ONEOK delivered the highest total return despite having the lowest initial yield, demonstrating that earnings growth and dividend growth are more important long-term factors than high starting yields.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics announced the grant of 57,000 restricted stock units (RSUs) to 11 newly hired employees as a material inducement for employment. The RSUs will vest over four years with 25% vesting annually, subject to continued employment. The company also announced that management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026.

Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. Management will participate in a fireside chat on Wednesday, September 16 at 1:50 p.m. ET. The company focuses on developing targeted topicals for chronic inflammatory skin diseases.

Arcutis Biotherapeutics shares are trading lower. The company announced its subsidiary Arcutis Canada secured Health Canada approval for roflumilast cream in pediatric atopic dermatitis patients.

Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.